Akeso Biopharma Is A Clinical Stage Biopharmaceutical Company Founded In 2012 And Listed On The Hong Kong Stock Exchangethe Company Focuses On The Discoverydevelopmentand Commercialization Of Innovative Biological Medicinesakeso Has Developed A Comprehensive Drug Development Platform Known As The Ace Platform And Utilizes A Unique Bi Specific Antibody Technology Called Tetrabody The Company Offers A Range Of Services Through Its Integrated R&D Innovation Systemincluding Research And Developmentmanufacturingand Commercializationakeso Has A Robust Pipeline With Over 50 Innovative Assets Targeting Major Diseases Such As Cancer And Autoimmune Disordersit Operates A Gmp Compliant Manufacturing System To Ensure High Quality Production And Has An Advanced Commercialization System For Global Distributionakeso S Product Portfolio Features Bispecific And Multispecific Antibodieswith Several Candidates In Clinical Trials And Six New Drugs Currently Available On The Market
